MarginsXMarginsX
Home › Data Desk › Licensing and milestone payments

Licensing and milestone payments

Automated articles on Licensing and milestone payments, built every day from SEC filings, prices and our own datasets.

All topics · Dilution · Offerings · Convertible notes · FDA approval · Licensing and milestone payments · At-the-market offering · Delistings · Mergers and acquisitions · Restaurants · Casinos · Foreign private issuer · Material weakness · Early-stage clinical trials · Oncology · FDA setbacks · Reverse split · Private placement (PIPE) · Warrants and inducements · Biofuels and renewable natural gas · Insider buying · Debt financing · Divestitures · Solar · Artificial intelligence · Equity line of credit · Late-stage clinical trials · Daily feature · Going-concern doubt · Week ahead · Customer concentration · Late filings · Weekly roundups · Rates and the dollar · Banking · Quarterly results · Dual-class shares · Inflation and interest rates · Share buybacks · AI data centers · Executive turnover · GPUs and accelerators · Big movers · IPO · Public offerings · SPAC · China exposure · Convertible preferred stock · Natural gas and LNG · Cryptocurrency · Bankruptcy · Tobacco and vaping · Related-party loans · Nasdaq deficiency notice · Payments and fintech · Alcoholic beverages · Oil and gas production · Delisting · Aerospace and aviation · Tariffs · Medical devices · 13G holders · Carbon and clean energy credits · Semiconductors · Cannabis · Electric vehicles · Name or ticker change · Aesthetics and dermatology · Pet products · Stablecoins · Critical minerals · Gold mining · Mineral exploration · Auditor changes · Drones · Cell and gene therapy · Defense and military · Exchange listing notices · OTC quotation · Battery energy storage · Authorized share increase · 13D stakes · Robotics · Market wrap · Dividend payments · Spin-offs · Carbon capture · Impairment charges · Firearms and ammunition · Reverse merger · Securities class actions · Generative AI · Layoffs and restructuring · Asset management and BDCs · Hydrogen and fuel cells · Joint ventures · REITs and real estate · Reverse splits · Data centers · Backlog and contracted revenue · Trucking and logistics · Agriculture · Wind power · Video games and esports · War and geopolitical risk · Insurance carriers · Medicare and Medicaid reimbursement

Gossamer Bio Inc. files an S-3 shelf registration

Gossamer Bio Inc. (GOSS) filed an S-3 on Nov 16, 2026, a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 16, 2026)

November 16, 2026 · data as of 2026-11-16

Vir Biotechnology Inc. puts a 424B5 prospectus supplement on file

On Nov 16, 2026, Vir Biotechnology Inc. (VIR) filed a 424B5: a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)

November 16, 2026 · data as of 2026-11-16

Rezolute Inc. files a 424B5 prospectus supplement

Rezolute Inc. (RZLT) filed a 424B5 on Nov 16, 2026, a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)

November 16, 2026 · data as of 2026-11-16

Context Therapeutics Inc.'s 10-Q carries going-concern doubt

In its 10-Q, filed Nov 10, 2026, Context Therapeutics Inc. (CNTX) disclosed substantial doubt that it can carry on as a going concern. (SEC EDGAR, 10-Q, Nov 10, 2026)

November 14, 2026 · data as of 2026-11-10

Kiora Pharmaceuticals Inc.'s 10-Q carries going-concern doubt

Kiora Pharmaceuticals Inc. (KPRX) told investors in its 10-Q on Nov 12, 2026 that there is substantial doubt it can continue operating as a going concern. (SEC EDGAR, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

ABVC BioPharma Inc. files a 424B4 prospectus supplement

ABVC BioPharma Inc. (ABVC) filed a 424B4 on Nov 13, 2026, a final prospectus with the offering's price. (SEC EDGAR, 424B4, Nov 13, 2026)

November 14, 2026 · data as of 2026-11-13

Vir Biotechnology Inc. files for an at-the-market share sale

Vir Biotechnology Inc. (VIR) filed a 424B5 on Nov 12, 2026 whose text describes an at-the-market offering, shares sold into the market over time through a sales agent. (SEC EDGAR, 424B5, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Evommune Inc. revenue down 100.0% in the quarter to Sep 30, 2026

The 10-Q that Evommune Inc. (EVMN) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Ovid Therapeutics Inc. has about 2.9 months of cash at its recent burn

The 10-Q that Ovid Therapeutics Inc. (OVID) filed on Nov 10, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

November 14, 2026 · data as of 2026-11-10

Capricor Therapeutics Inc. reports $44.3M of cash, about 4.4 months at its recent burn

Capricor Therapeutics Inc. (CAPR) filed its 10-Q on Nov 10, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

November 14, 2026 · data as of 2026-11-10

Zymeworks Inc. grows revenue 828.7% in the quarter to Sep 30, 2026

The 10-Q that Zymeworks Inc. (ZYME) filed on Nov 9, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026)

November 14, 2026 · data as of 2026-11-09

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Follow topics in MarginsX